KBC Group NV Makes New Investment in Amedisys, Inc. (NASDAQ:AMED)

KBC Group NV purchased a new stake in Amedisys, Inc. (NASDAQ:AMED) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 655 shares of the health services provider’s stock, valued at approximately $63,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Innealta Capital LLC purchased a new position in Amedisys during the 2nd quarter valued at about $64,000. Signaturefd LLC increased its holdings in Amedisys by 88.2% during the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock worth $104,000 after acquiring an additional 530 shares during the period. CWM LLC lifted its stake in Amedisys by 14.5% in the 3rd quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock worth $211,000 after purchasing an additional 277 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Amedisys during the 3rd quarter valued at $243,000. Finally, GAM Holding AG bought a new position in shares of Amedisys in the second quarter worth $275,000. 94.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft lowered Amedisys from a “buy” rating to a “hold” rating and set a $101.00 target price on the stock. in a research note on Monday, July 29th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $100.67.

Amedisys Stock Performance

Amedisys stock opened at $90.64 on Friday. Amedisys, Inc. has a fifty-two week low of $88.81 and a fifty-two week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The stock has a market cap of $2.97 billion, a P/E ratio of 35.97, a price-to-earnings-growth ratio of 1.89 and a beta of 0.78. The firm’s fifty day moving average price is $95.34 and its 200-day moving average price is $95.75.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.19). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $587.67 million for the quarter, compared to the consensus estimate of $586.75 million. During the same period last year, the firm earned $0.98 EPS. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. On average, equities research analysts expect that Amedisys, Inc. will post 4.55 earnings per share for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.